The oral biologics research line of our lab focuses on developing innovative biotechnology that modulates GI-related disease by tackling local targets. Our group is evaluating the use of biopharmaceuticals for human GI indications of pressing unmet clinical need in running academic research programs. By means of yeast/plant seed-based production process that offers high scalability and a food-grade final product, we aim to overcome current-day limitations associated with oral administration of biologics. We also have a longstanding research line on the use of plasma protein glycome and plasma DNA epigenome alterations as an information source for new diagnostics